The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model

Biomaterials

Volumn 31, Issue 5, 2010, Pages 916-922

  Xu, Zhenghong ^a   Zhang, Zhiwen ^a   Chen, Yi ^a   Chen, Lingli ^a   Lin, Liping ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Chemotherapy; Co delivery; Docetaxel; Gene therapy; Hepatocellular carcinoma; Survivin

Indexed keywords

ANTI-TUMOR AGENTS; ANTI-TUMOR EFFICACY; ANTITUMOR DRUGS; CELLULAR UPTAKE; CHEMOTHERAPEUTIC DRUGS; COMBINED TREATMENT; DOCETAXEL; EFFICIENT STRATEGY; ENCAPSULATION EFFICIENCY; GENE THERAPEUTICS; GENE THERAPY; HEPATOCELLULAR CARCINOMA; HEPATOCELLULAR CARCINOMA CELL; HEPATOMA CELLS; LIGAND-RECEPTOR; LIPOFECTAMINE; NANO-ASSEMBLIES; NUCLEAR DELIVERY; NUCLEAR TRANSFER; REPORTER GENE; SURVIVIN; TRANSFECTION EFFICIENCY;

CELL CULTURE; CHEMOTHERAPY; CYTOTOXICITY; ENCAPSULATION; GENETIC ENGINEERING; LIGANDS; NUCLEIC ACIDS; POLYETHYLENE GLYCOLS;

ENZYME INHIBITION;

DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DISULFIDE; DOCETAXEL; DRUG CARRIER; FOLIC ACID; LIPOFECTAMINE; LIPOFECTAMINE 2000; MACROGOL; PLASMID DNA; PROTAMINE SULFATE; SURVIVIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DNA; DRUG CARRIERS; FEMALE; GENE THERAPY; MATERIALS TESTING; MICE; MICE, NUDE; NANOSTRUCTURES; TAXOIDS; TREATMENT OUTCOME;

EID: 70649115439     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.09.103     Document Type: Article

References (35)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Qin L.X., and Tang Z.Y. The prognostic significance of clinical and pathological feature in hepatocellular carcinoma. World J Gastroenterol 8 (2002) 193-199
3. Wong H.L., Bendayan R., Rauth A.M., Li Y.Q., and Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59 (2007) 491-504
4. Gueritte-Voegelein F., Guenard D., Lavelle F., Le Goff M.T., Mangatal L., and Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34 (1991) 992-998
5. Wenzel C., Locker G.J., Schmidinger M., Rudas M., Taucher S., Gnant M.F., et al. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel plus granulocyte colony stimulating factor. Anticancer Drugs 13 (2002) 67-74
6. Cascinu S., Graziano F., Barni S., Labianca R., Comella G., Casaretti R., et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 84 (2001) 470-474
7. Ryan D.P., Kulke M.H., Fuchs C.S., Grossbard M.L., Grossman S.R., and Morgan J.A. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94 (2002) 97-103
8. Sinibaldi V.J., Carducci M.A., Moore-Cooper S., Laufer M., Zahurak M., and Eisenberger M.A. Phase II evaluation of docetaxel plus oneday oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94 (2002) 1457-1465
9. Geng C.X., Zeng Z.C., and Wang J.Y. Docetaxel inhibits SMMC-7221 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 9 (2003) 696-700
10. Lin H.L., Liu T.Y., Chau G.Y., Lui W.Y., and Chi C.W. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89 (2000) 983-994
11. Hebbar M., Ernst O., Cattan S., Dominguez S., Oprea C., and Mathurin P. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 70 (2006) 154-158
12. Ikeguchi M., Ueda T., and Salatani T. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 11 (2002) 33-40
13. Giodini A., Kallio M.J., and Wall N.R. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62 (2002) 2462-2467
14. Notarbartolo M., Cervello M., Giannitrapani L., Meli M., Poma P., Dusonchet L., et al. Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells. Ann NY Acad Sci 1028 (2004) 289-293
15. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
16. Giodini A., Kallio M.J., Wall N.R., Gorbsky G.J., Tognin S., Marchisio P.C., et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62 (2002) 2462-2467
17. Colella G., Zaffaroni N., Pennati M., Benini E., and Daidone M.G. Expression of the anti-apopotosis gene survivin correlates with taxol resistance in human ovarian cancer. Proc Am Assoc Cancer Res 42 (2001) 302
18. Rayburn E.R., and Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?. Drug Discov Today 13 (2008) 513-521
19. Hwang L. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci 13 (2006) 453-468
20. Drummond D.C., Zignani M., and Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39 (2000) 409-460
21. Hafez I.M., and Cullis P.R. Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev 47 (2001) 139-148
22. Meng F., Hennink W.E., and Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 30 (2009) 2180-2198
23. Go Y.M., and Jones D.P. Redox compartmentalization in eukaryotic cells. Biochim Biophys Acta 11 (2008) 1273-1290
24. Sorgi F.L., Bhattacharya S., and Huang L. Protamine sulfate enhances lipid mediated gene transfer. Gene Ther 4 (1997) 961-968
25. Masuda T. Evaluation of nuclear transfer and transcription of plasmid DNA condensed with protamine by microinjection: the use of a nuclear transfer score. FEBS Lett 579 (2005) 2143-2148
26. Kirpotin D., Hong K., Mullah N., Papahadjopoulos D., and Zalipsy S. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 388 (1996) 115-118
27. Longmuir K.J., Haynes S.M., Dickinson M.E., Murphy J.C., Willson R.C., and Waring A.J. Optimization of a peptide/non-cationic lipid gene delivery system for effective microinjection into chicken embryo in vivo. Mol Ther 4 (2001) 66-74
28. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., et al. Folate-targeted, cationic liposomemediated gene transfer into disseminated peritoneal tumors. Gene Ther 9 (2002) 1542-1550
29. Hofland H.E., Masson C., and Iginla S. Folate targeted gene transfer in vivo. Mol Ther 5 (2002) 739-744
30. Ni S., Stephenson S.M., and Lee R.J. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 22 (2002) 2131-2135
31. Honda R., Korner R., and Nigg E.A. Exploring the functional interactions between aurora B, INCENP, and surviving in mitosis. Mol Biol Cell 14 (2003) 3325-3341
32. Li S.D., and Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 13 (2006) 1313-1319
33. Gabizon A., Shmeeda H., Horowitz A.T., and Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG-conjugates. Adv Drug Deliv Rev 56 (2004) 1177-1192
34. Brummelkamp T.R., Bernards R., and Agami R. A system of stable expression of short interfering RNAs in mammalian cell. Science 296 (2002) 550-553
35. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 (1986) 6387-6392